Drugs / MTX
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04178850 Background | Oct 2017 → Dec 2020 | rheumatoid arthritis | Genor Biopharma Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MTX | “MTX:Dosage and administration at enrollment are maintained (10\~15mg/week), oral administration, a total of 30 doses” NCT04178850 ↗ |
| Route | Oral | “oral administration” NCT04178850 ↗ |